Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONS-5010 vs Ranibizumab in Wet Age-related Macular Degeneration
NCT03834753Phase 3Completed
- Sponsor
- Outlook Therapeutics
- Start
- Jun 2019
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in age-related macular degeneration (AMD) (2 arms), sponsored by Outlook Therapeutics. Primary endpoint: Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA) at 11 months. Started Jun 2019; status: completed.
02
Drugs
bevacizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT03834753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834753.